Exploiting the 5‐Amino‐11H‐Indolo[3,2‐c]isoquinoline Core to Achieve Better G‐Quadruplex Ligands for Cancer Therapy
ChemMedChem · 2025
DOI: 10.1002/cmdc.202401019 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Israa M Aljnadi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Research Institute for Medicines (iMed.Ulisboa), Universidade de Lisboa, 1649-003, Lisbon, Portugal. Hauptthemen laut MEDLINE: G-Quadruplexes, Antineoplastic Agents, Isoquinolines, Indoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: FCT and Portugal 2020 to the Portuguese Mass Spectrometry Network, Fundação para a Ciência e Tecnologia, Project HfPT - Health from Portugal.
Abstract (Originalsprache)
G‐quadruplexes (G4) are secondary structures that can form within guanine‐rich DNA sequences and have cell proliferation regulatory functions. Targeting DNA G4 structures has emerged as a promising anticancer therapy, highlighting the need for new G4 ligands with reduced number of cationic groups to ensure lower toxicity. Herein, the synthesis of mono‐ and di‐substituted 5‐amino‐11H‐indolo[3,2‐ c ]isoquinolines is reported. Fluorescence spectroscopy studies indicate that substitution in position 11 dictates the preference of binding to different G4. Compound 10 , which features an ethylpyrrolidine side chain, demonstrates a binding preference by one order of magnitude for parallel c‐MYCG4 ( K b = 10 7 m −1 ), over parallel k‐RASG4 ( K b = 10 6 m −1 ), and hybrid TeloG4 and dsDNA ( K b = 10 5 m −1 ). Molecular docking studies reveal that 10 can bind not only to the flat G‐quartets but also to bridge between two loops of c‐MYCG4 through hydrogen bonds, which may explain its capacity to discriminate between G4. Moreover, 10 drastically reduces the cell viability of breast cancer cells at a concentration of 10 μ m . Overall, herein, the discovery of a new potent and selective G4 ligand, with reduced number of side chains and with antiproliferative activity in cancer cells, is reported, which deserves to be further investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Research Institute for Medicines (iMed.Ulisboa), Universidade de Lisboa, 1649-003, Lisbon, Portugal.
- BioISI - Biosystems and Integrative Sciences Institute, Faculty of Sciences, Universidade de Lisboa, Campo Grande, C8 building, 1749-016, Lisboa, Portugal.
- Accelbio: Collaborative Laboratory to Foster Translation and Drug Discovery, 3030-197, Cantanhede, Portugal.
- Centro de Química Estrutural (CQE) and Instiute of Molecular Sciences (IMS), Departamento de Química, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001, Lisboa, Portugal.
ORCID-Profile: Alexandra Paulo
Förderung
- FCT and Portugal 2020 to the Portuguese Mass Spectrometry Network
- Fundação para a Ciência e Tecnologia
- Project HfPT - Health from Portugal
- Agendas/Aalianças mobilizadoras para a Inovação Empresarial, and CoLAB AccelBio
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Aljnadi, I. M., Bahls, B., Duarte, N., Victor, B. L., Mendes, E., Camões, S. P., Miranda, J. P., Maçôas, E., & Paulo, A. (2025). Exploiting the 5‐Amino‐11H‐Indolo[3,2‐c]isoquinoline Core to Achieve Better G‐Quadruplex Ligands for Cancer Therapy. ChemMedChem. https://doi.org/10.1002/cmdc.202401019
Vancouver
Aljnadi IM, Bahls B, Duarte N, Victor BL, Mendes E, Camões SP, et al. Exploiting the 5‐Amino‐11H‐Indolo[3,2‐c]isoquinoline Core to Achieve Better G‐Quadruplex Ligands for Cancer Therapy. ChemMedChem. 2025. doi:10.1002/cmdc.202401019
BibTeX
@article{Aljnadi2025,
author = {Aljnadi, Israa M and Bahls, Barbara and Duarte, Noélia and Victor, Bruno L and Mendes, Eduarda and Camões, Sergio P and Miranda, Joana P and Maçôas, Ermelinda and Paulo, Alexandra},
title = {Exploiting the 5‐Amino‐11H‐Indolo[3,2‐c]isoquinoline Core to Achieve Better G‐Quadruplex Ligands for Cancer Therapy},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202401019}
}
EUVIMED